ERBB3 and prostate carcinoma: IHC showed that vehicle-treated PC3 xenografts were HER2-low and HER3-low with robustly infiltrating Aspn+ stroma, which is consistent with prostate cancer metastases in patients (Figure 10, H and I, and Supplemental Figure 9, K–N).